In the United States,<unk>  is indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type2 diabetes. In the European Union,<unk>  is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type2 diabetes in adults.
Finerenone
Androstanolone
Lynestrenol
Androstanolone valerate
Allylestrenol
Androstanolone enanthate
Androstanolone propionate
Protollin